Potential lipid-based strategies of amphotericin B designed for oral administration in clinical application
Amphotericin B (AmB) is regarded as a first-line therapy against life-threatening invasive fungal infections. Due to its poor oral bioavailability, AmB is restricted to intravenous administration in clinical practice. As science continues to move forward, two lipid-based formulations are successfully developed for oral AmB administration, currently undergoing phase I clinical trials. Encouragingly, lipid-AmB conjugates with emulsions also exhibit a better bioavailability, which may be another strategy to design oral AmB formulation in clinical practice. Thus, this review mainly focused on the two lipid-based formulations in clinical trials, and discussed the potential perspectives of AmB-lipid conjugation-loaded nanocochleates and emulsions.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:30 |
|---|---|
| Enthalten in: |
Drug delivery - 30(2023), 1 vom: 03. Dez., Seite 2161671 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhong, Xiaoming [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
7XU7A7DROE |
|---|
| Anmerkungen: |
Date Completed 06.01.2023 Date Revised 11.01.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1080/10717544.2022.2161671 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM351129693 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM351129693 | ||
| 003 | DE-627 | ||
| 005 | 20231226050614.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/10717544.2022.2161671 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1170.xml |
| 035 | |a (DE-627)NLM351129693 | ||
| 035 | |a (NLM)36601799 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhong, Xiaoming |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Potential lipid-based strategies of amphotericin B designed for oral administration in clinical application |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.01.2023 | ||
| 500 | |a Date Revised 11.01.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Amphotericin B (AmB) is regarded as a first-line therapy against life-threatening invasive fungal infections. Due to its poor oral bioavailability, AmB is restricted to intravenous administration in clinical practice. As science continues to move forward, two lipid-based formulations are successfully developed for oral AmB administration, currently undergoing phase I clinical trials. Encouragingly, lipid-AmB conjugates with emulsions also exhibit a better bioavailability, which may be another strategy to design oral AmB formulation in clinical practice. Thus, this review mainly focused on the two lipid-based formulations in clinical trials, and discussed the potential perspectives of AmB-lipid conjugation-loaded nanocochleates and emulsions | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a AmB | |
| 650 | 4 | |a clinical application | |
| 650 | 4 | |a cochleates | |
| 650 | 4 | |a emulsions | |
| 650 | 4 | |a encochleates | |
| 650 | 4 | |a oral formulation | |
| 650 | 7 | |a Amphotericin B |2 NLM | |
| 650 | 7 | |a 7XU7A7DROE |2 NLM | |
| 650 | 7 | |a Antifungal Agents |2 NLM | |
| 650 | 7 | |a Emulsions |2 NLM | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Macrolides |2 NLM | |
| 650 | 7 | |a Lipids |2 NLM | |
| 700 | 1 | |a Yang, Jianqiong |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Hongyan |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Zhiwen |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Ping |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drug delivery |d 1996 |g 30(2023), 1 vom: 03. Dez., Seite 2161671 |w (DE-627)NLM09361134X |x 1521-0464 |7 nnns |
| 773 | 1 | 8 | |g volume:30 |g year:2023 |g number:1 |g day:03 |g month:12 |g pages:2161671 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/10717544.2022.2161671 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 30 |j 2023 |e 1 |b 03 |c 12 |h 2161671 | ||